Clinical Trials Logo

Stage III Ovarian Cancer clinical trials

View clinical trials related to Stage III Ovarian Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05995860 Active, not recruiting - Clinical trials for Stage IV Ovarian Cancer

Study of a Rapid Triadic Communication Intention Elicitation Intervention to Improve Supportive Oncology Care Delivery

PRECursOr
Start date: June 14, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to help test an idea designed to foster more supportive talk between providers (doctors or nurse practitioners), patients, and caregivers during an outpatient oncology appointment. A caregiver is the person the patient identifies is primarily involved in their healthcare. This study is collecting your reaction to this idea in order to understand needed changes before we introduce the idea to a larger group of patients.

NCT ID: NCT04204811 Active, not recruiting - Ovarian Cancer Clinical Trials

Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy

Start date: December 16, 2019
Phase:
Study type: Observational

The purpose of this study is evaluate whether a prehabilitation program is feasible and useful for women with advanced ovarian cancer receiving chemotherapy in preparation for debulking surgery.

NCT ID: NCT03154190 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Start date: August 8, 2017
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management.

NCT ID: NCT02124421 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

HOT: HIPEC in Ovarian Cancer as Initial Treatment

CRS/HIPEC
Start date: April 2014
Phase: Phase 2
Study type: Interventional

Community hospital based phase II (prospective randomized) study to evaluate the toxicity of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in newly diagnosed, otherwise untreated, advanced stage (stage III/IV) epithelial ovarian, fallopian tube, and primary peritoneal cancer.

NCT ID: NCT01650376 Active, not recruiting - Uterine Cancer Clinical Trials

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Start date: August 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) of the investigational agent, olaparib, to give in combination with carboplatin and paclitaxel in patients with relapsed ovarian cancer or uterine cancer. Furthermore, the investigators intend to study the safety and tolerability of the study treatment, response to treatment, time to disease progression, and overall survival.